Selective ERβ Agonists Exert Anti-Proliferative and Proapoptotic Effects on ERα+ Breast Cancer Cell Lines and Results in Increased Expression of FOXO 1/3 Proteins in ERα+ Breast Cancer Cell Lines. Here, ESR2 is linked to breast carcinoma.